Dianthus Therapeutics (DNTH) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Liquidia (LQDA) over the past year, gaining 104.0% versus a gain of 87.0%. Over five years, LQDA leads with a +1224.3% price change compared with -12.8% for DNTH. Liquidia is the larger company by market cap ($4.90 billion vs $4.76 billion), about 1.0 times the size.
Liquidia converts more of its revenue into profit, with a net margin of -43.5% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | LQDA |
|---|---|---|
| Share price | $84.55 | $54.43 |
| Market cap | $4.76B | $4.90B |
| 1-day change | -0.33% | -3.88% |
| YTD return | +105.17% | +57.81% |
| 1-year return | +103.98% | +86.98% |
| 5-year return | -12.80% | +1224.33% |
| Forward P/E | — | 15.12 |
| EPS (TTM) | $-4.08 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $158.32M |
| Revenue growth (YoY) | -67.35% | +1031.18% |
| Net income (latest FY) | $-162.34M | $-68.92M |
| Operating margin | -8739.34% | -32.45% |
| Net margin | -7973.33% | -43.53% |
| 52-week high | $117.88 | $93.61 |
| 52-week low | $35.84 | $22.31 |
| Distance from 52-week high | -28.27% | -41.85% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +64.70% | +21.50% |
| Average volume | 848.96K | 3.52M |
| Shares outstanding | 56.31M | 90.11M |
| Employees | 92 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed LQDA by 17.0 percentage points over the past year.
- Liquidia is more profitable, keeping -43.5 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
DNTH vs LQDA FAQ
Which is bigger, Dianthus Therapeutics or Liquidia?
Liquidia (LQDA) is larger, with a market capitalization of $4.90B compared with $4.76B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or LQDA?
DNTH returned +103.98% over the past 12 months, compared with +86.98% for LQDA (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.